In case you needed any more reasons why @philseo is the best @rheum_cat , this is his first slide @RheumNow #RNL2024 https://t.co/Ar0v7sQuuX

• https://twitter.com/RichardPAConway/status/1751614606374764657/photo/1

Dr @anisha_dua's takehome points for treating GPA in 2024 *RTX and CYC are both effective followed by RTX at least 500mg q 6 mo for at least 2 years *PLEX not generally used, but may be effective in preventing ESKD *Rapid GC tapering may not be suitable for all pts *Avacopan is… https://t.co/haI19Sgpmu https://t.co/jhjXLwd0Uw

• https://twitter.com/i/web/status/1751613576983326899
• https://twitter.com/uptoTate/status/1751613576983326899/photo/1

PJP prophylaxis in GPA. Always a trade off but these things are not created equal. PJP or sepsis are much worse on average than the AEs @anisha_dua @RheumNow #RNL2024 https://t.co/9sECd7fSRk

• https://twitter.com/RichardPAConway/status/1751613348032962607/photo/1

Remission maintenance in AAV. First 2 years is clear - fixed dose RTX is superior. After that it is clear that following ANCA is suboptimal, could consider either B-cell return dosing or ongoing fixed dosing @anisha_dua @RheumNow #RNL2024 https://t.co/0Elir88L9U

• https://twitter.com/RichardPAConway/status/1751613096366326061/photo/1

Maintenance issues in GPA. Clear messages. 1. RTX is best 2. Fixed 6-monthly RTX best for 1st 2 years. 3. Don't stop RTX at 2 years! @anisha_dua @RheumNow #RNL2024 https://t.co/jS3jWm0CcS

• https://twitter.com/RichardPAConway/status/1751612592920137951/photo/1

The answer to "always" is "always" no, correct? PEXIVAS low dose is a great baseline plan, but always adjust in light of the individual patient both upfront and especially if things aren't working out @anisha_dua @RheumNow #RNL2024 https://t.co/RPnpAdB1eG

• https://twitter.com/RichardPAConway/status/1751610831576698888/photo/1

Rapid GC taper in ANCA vasculitis #RNL2024 @RheumNow @anisha_dua PEXIVAS - reduced GC is safe, decreased ifns Retrospective real world - 234 pts. Reduced dose GC+RTX increased death/ESKD HR 2.42. No difference in infections https://t.co/SWIUSyVbWb

• https://twitter.com/ericdeinmd/status/1751610127252148272/photo/1

Great talk @anisha_dua re:AAV, solid updates on mgmt decisions Looking forward to debating this study with @lastwalsh w/@MatsJunek moderating... @TerrierBen any updates on when your RWD study will be published? @RheumNow https://t.co/ywVaOIp2WJ

• https://twitter.com/EBRheum/status/1751609973082124761/photo/1

Contrasing ACR/VF and EULAR GPA guidelines from @anisha_dua @RheumNow #RNL2024 https://t.co/RLJx9fJHGk

• https://twitter.com/RichardPAConway/status/1751609824973139984/photo/1

"Real world studies: When people stop being polite and start getting real." Dr @anisha_dua #RNL2024 Comparing Walsh to Nagle in terms of primary outcomes, regimens, pt populations, and plasma exchange. @RheumNow https://t.co/io8OGnWxdS

• https://twitter.com/uptoTate/status/1751609810573832670/photo/1

Is there data for PLEX in GPA? @anisha_dua #RNL2024 @RheumNow PEXIVAS negative study But subgroups show decreased dialysis... But, no improvement in mortality and increased infection risk https://t.co/K9VbcNNsge

• https://twitter.com/ericdeinmd/status/1751608903714926770/photo/1

#RNL2024 @RheumNow @anisha_dua Throwing the kitchen sink in severe GPA CYC + RTX combo - sick population (median GFR 9, 47% on HD, 52% DAH, all received PLEX too) - 85% survival, 69% not ESKD, low rates of relapse (13% at 36 mos) But, prolonged B cell depletion, aggressive Rx https://t.co/9AZFMQ3o9P

• https://twitter.com/ericdeinmd/status/1751608396627718341/photo/1

#RNL2024 is up and at ‘em this Sunday morning! ⁦@RheumNow⁩ ⁦@KDAO2011⁩ ⁦@RichardPAConway⁩ ⁦@ericdeinmd⁩ https://t.co/AtL9QiRnW4

• https://twitter.com/uptoTate/status/1751607229113921852/photo/1

@anisha_dua reviews differences between EULAR vs ACR Vasculitis guidelines #RNL2024 @RheumNow https://t.co/1aIbnX5KBI

• https://twitter.com/KDAO2011/status/1751607655934709827/photo/1

@anisha_dua reviews GPA management in 2024. Here are your ACR/VF 2021 and EULAR 2022 guideline updates. Review these regimen options for your patients. #RNL2024 @RheumNow https://t.co/SvQoe0YKKV

• https://twitter.com/uptoTate/status/1751607745214587184/photo/1